FDA recommends approval of Perjeta for HER2+ Breast Cancer

An FDA advisory panel has voted in favor of recommending accelerated approval of Perjeta (pertuzumab), from Roche, as a neoadjuvant treatment for HER2-positive early-stage Breast Cancer. The panel said that in combination with Roche's Herceptin (trastuzumab), it had a "favourable benefit-to-risk" ratio. A decision on whether to approve Perjeta for this indication is expected by the end of October.